956117-07-0

Upstream product

• 438035-28-0 D-5,6-O-(1-methylethylidene)-1,4-bis-O-(phenylmethyl)-myo-inositol 
• 438035-23-5 (3aS,4R,7R,7aS)-3a,4,7,7a-tetrahydro-2,2-dimethyl-4,7-bis(phenylmethoxy)-1,3-benzodioxole 
• 371155-64-5 (3aS,4R,7R,7aS)-3a,4,7,7a-tetrahydro-2,2-dimethyl-1,3-benzodioxole-4,7-diol 
• 160636-42-0 (3aS,4S,4aR,7aS,8S,8aS)-4,8-Bis-benzyloxy-2,2,6,6-tetramethyl-hexahydro-benzo[1,2-d;4,5-d']bis[1,3]dioxole 
• 160636-46-4 1D-4-O-benzyl-2,3:5,6-di-O-isopropylidene-myo-inositol 
• 68737-75-7 1L-4-O-benzyl-myo-inositol 
• 956116-97-5 L-1,3,4,5-tetra-O-methoxymethyl-myo-inositol 
• 956031-35-9 L-2-O-benzoyl-6-O-benzyl-1,3,4,5-tetra-O-methoxymethyl-myo-inositol 
• 956031-33-7 L-2-O-benzoyl-6-O-benzyl-myo-inositol 

Relevant academic research and scientific papers

Divergent synthesis of all possible optically active regioisomers of myo-inositol mono- and bisphosphates

All possible optically active regioisomers of myo-inositol mono- and bisphosphates were synthesized using inositol derivatives suitably protected with various protecting groups (IRns) as key intermediates. A series of procedures including Novozym 435 cata